NCT01050426终止2 期
A Multicentre Randomised Phase II Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine Plus Capecitabine in Patients With Locally Advanced Pancreatic Cancer (PERU)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 17
- 试验地点
- 15
- 主要终点
- One year overall survival, measured from the date of registration.
研究概览
简要总结
The purpose is to assess the overall survival of patients receiving either UFT/LV + radiotherapy (RT) or UFT/LV + Cetuximab + RT after neo-adjuvant chemotherapy.
详细描述
Locally advanced pancreatic cancer carries a poor prognosis with no survival advantage of CRT over chemotherapy alone. 4 Phase II- III studies patients without disease progression after 3 months of systemic chemotherapy and CRT had a longer survival than those continuing on chemotherapy. Therefore chemotherapy followed by CRT may be a better approach. Also the effect of blocking EGFR will be evaluated in locally advanced pancreatic cancer. Gemcitabine and capecitabine combination will be used as neo-adjuvant chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histological or cytological diagnosis of adeno- or undifferentiated non-small cell carcinoma of pancreas.
- •Considered to be unresectable based on following: extensive peri-pancreatic lymph node involvement, encasement or occlusion of the SMV or SMV/portal vein confluence, direct involvement of SMA, coeliac axis, inferior vena cava or aorta.
- •Performance status 0-2
- •No evidence of metastatic disease as determined by CT scan/ other investigations
- •Adequate bone marrow function with platelets>100^9/l; WBC>3x10^9/l;neutrophils> 1.5x10^9/l
- •Serum bilirubin ,1.5 x ULN and transaminases < 2.5 x ULN
- •Calculated/measured GFR >50ml/min
- •No concurrent uncontrolled medical condition
- •No active malignant disease other than non-melanotic skin cancer or carcinoma in situ of the uterine cervix over the last 10 years
- •Life expectancy > 3months
- •Adequate contraceptive precautions
- •Informed written consent
排除标准
- •medical or psychiatric conditions that compromise the patient's ability to give informed consent
- •Presence of met. disease
- •Concurrent uncontrolled medical conditions
- •Any previous chemo/RT or any investigational treatment for advanced pancreatic cancer.
- •Adjuvant chemo + fluoropyrimidine or gemcitabine within 12months of trial entry
- •Adjuvant RT with/without chemo for pancreatic cancer.
- •Pregnancy/breast feeding
- •Patients with known malabsorption syndromes ro a lack of physical treatment of the upper GI tract.
- •Patients with a known hypersensitivity to 5-FU or with a DPD deficiency.
- •Clinically significant CVD
结局指标
主要结局
One year overall survival, measured from the date of registration.
时间窗: one year
次要结局
- Objective response rate(three years)
- Quality of life(up to 3 years)
- Evaluation of the role of FDG-PET in predicting overall survival, progression free survival and objective response rate in locally advanced pancreatic cancer.(up to 3 years)
- Characterise safety profile of UFT/leucovorin, radiotherapy with or without cetuximab following induction gemcitabine plus capecitabine in patients with locally advanced pancreatic cancer(three years)
- Pattern of failure(up to 3 years)
- Evaluation of molecular and genetic predictors of response to anti-EGFR treatment(up to 3 years)
- Progression free survival(three years)
- Evaluation of changes in diffusion weighted MRI parameters in pancreatic cancer patients before and after treatment.(up to 3 years)
研究者
研究点 (15)
Loading locations...
相似试验
招募中
2 期
Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLCExtensive Stage Lung Small Cell CancerNCT06350162Zhejiang Cancer Hospital100
进行中（未招募）
2 期
Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt CoursesDiffuse Intrinsic Pontine GliomaNCT03620032Fondazione IRCCS Istituto Nazionale dei Tumori, Milano54
招募中
不适用
Radiotherapy Combined with Systemic Therapy Versus Systemic Therapy for Oligometastatic UTUCsOligometastatic DiseaseUreter CancerRenal Pelvic CarcinomaNCT06652022102
尚未招募
2 期
Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advanced Esophageal Squamous Cell CarcinomaEsophageal Squamous Cell CarcinomaNCT06468644Fujian Cancer Hospital60
撤回
2 期
Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of Stage IB e IVA UCC(CORUS)CarcinomaAdenocarcinomaUterine Cervix Adenosquamous CarcinomaNCT01301612Eurofarma Laboratorios S.A.